Skip to main content
Tilaknagar Industries Ltd logo

Tilaknagar Industries Ltd — Investor Relations & Filings

Ticker · TI ISIN · INE133E01013 LEI · 894500IYPP2CKQNUR875 BSE.NS Manufacturing
Open in API
Filings indexed 1,830 across all filing types
Latest filing 2024-02-13 Call Transcript
Country IN India
Listing BSE.NS TI

About Tilaknagar Industries Ltd

https://tilind.com/

Tilaknagar Industries Ltd. is a manufacturer and distributor of Indian Made Foreign Liquor (IMFL). Established in 1933, the company specializes in the production of spirits, with a dominant presence in the brandy segment. Its flagship brand, Mansion House Brandy, is one of the highest-selling brandy brands globally. Other notable products include Courrier Napoleon Brandy, Madiraa Rum, and Senate Royale Whisky. The company operates multiple manufacturing facilities and bottling units, leveraging distillation technologies to maintain product consistency. Tilaknagar Industries maintains an extensive distribution network, catering to diverse consumer preferences across domestic and international markets. The organization focuses on brand building, product innovation, and operational efficiency to sustain its market leadership.

Recent filings

Filing Released Lang Actions
Please find enclosed Link of Audio recording of Earnings conference Call held for Q3FY24 results.
Call Transcript Classification · 80% confidence The document is a short letter addressed to stock exchanges referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the availability of the audio recording of the earnings conference call for Q3FY24 results and provides a link to access it. The document does not contain the transcript or detailed financial data but only informs about the availability of the call recording. According to the classification rules, announcements about earnings calls or their recordings fall under Call Transcript (CT) if the full transcript is provided, but here only the audio recording availability is announced. Since it is an announcement of the earnings call recording and not the transcript or financial results themselves, the best fit is Call Transcript (CT) with moderate confidence, as it relates directly to the earnings call content.
2024-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the availability of the audio recording of the earnings conference call for Q3FY24 results and provides a link to access it. The document does not contain the transcript or detailed financial data but is an announcement about the call recording. Therefore, it is not a full Call Transcript (CT) but rather a Regulatory Filing (RNS) announcing the availability of the call recording. The document length is only 1422 characters, supporting that it is an announcement rather than a full report or transcript.
2024-02-13 English
Please find enclosed herewith statement of Deviation or variation for Quarter and Nine months ended December 31, 2023
Regulatory Filings Classification · 95% confidence The document is a Statement of Deviation or Variation for the quarter ended December 31, 2023, submitted under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports on the utilization of funds raised through preferential issues and confirms no deviation for the quarter. The document is addressed to stock exchanges and signed by the Company Secretary and CFO. It is a regulatory compliance filing related to fund utilization and does not contain comprehensive financial statements or detailed financial performance data. The document length is 4274 characters, which is relatively short and focused on compliance reporting rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a full Annual Report, Interim Report, or Capital/Financing Update.
2024-02-12 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a Statement of Deviation or Variation for the quarter ended December 31, 2023, submitted under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports on the utilization of funds raised through preferential issues and confirms no deviation for the quarter. The document is an official regulatory compliance filing related to fund utilization and does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory announcement about fund usage compliance rather than a full financial report or audit report. The document length is 4274 characters, which is relatively short and focused on regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a full Annual Report, Interim Report, or Capital/Financing Update.
2024-02-12 English
Please find enclosed here with earnings presentation for Unaudited Financial results for Quarter and nine months ended December 31, 2023
Regulatory Filings
2024-02-12 English
Investor Presentation
Regulatory Filings
2024-02-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.